News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,434 Results
Type
Article (8024)
Company Profile (140)
Press Release (476174)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166777)
Career Advice (305)
Deals (25743)
Drug Delivery (7)
Drug Development (52880)
Employer Resources (14)
FDA (9762)
Job Trends (8575)
News (238268)
Policy (17926)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (25)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33156)
ALS (104)
Alzheimer's disease (973)
Antibody-drug conjugate (ADC) (263)
Approvals (10368)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (206)
Automation (28)
Bankruptcy (262)
Best Places to Work (6958)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (506)
Cancer (3629)
Cardiovascular disease (217)
Career advice (245)
Career pathing (1)
CAR-T (173)
Celiac Disease (1)
Cell therapy (477)
Cervical cancer (34)
Clinical research (47840)
Collaboration (1237)
Commercialization (3)
Compensation (1445)
Complete response letters (34)
COVID-19 (754)
CRISPR (63)
C-suite (736)
Cystic fibrosis (85)
Data (5608)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4176)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73590)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87577)
Executive appointments (699)
FDA (12363)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (908)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (289)
Government (943)
Grass and pollen (2)
Guidances (281)
Healthcare (9312)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (942)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5196)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (506)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (527)
Marketing (8)
MASH (118)
Medical device (8650)
Medtech (8790)
Mergers & acquisitions (14379)
Metabolic disorders (703)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1816)
NextGen: Class of 2026 (3150)
Non-profit (841)
Obesity (222)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (501)
Peanut (31)
People (41216)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15457)
Phase 2 (21367)
Phase 3 (14387)
Pipeline (7160)
Policy (18)
Postmarket research (1570)
Preclinical (6540)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3019)
Recruiting (6)
Regulatory (14786)
Reports (19)
Research institute (581)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (317)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (93)
Last 7 days (497)
Last 30 days (1643)
Last 365 days (19148)
2026 (11939)
2025 (19255)
2024 (22990)
2023 (26538)
2022 (34591)
2021 (37177)
2020 (33487)
2019 (23277)
2018 (17468)
2017 (18766)
2016 (17918)
2015 (24263)
2014 (21685)
2013 (18135)
2012 (20223)
2011 (20440)
2010 (20333)
Location
Africa (228)
Alabama (72)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17880)
Australia (2098)
California (11865)
Canada (3116)
China (515)
Colorado (479)
Connecticut (405)
Delaware (207)
Europe (24624)
Florida (1773)
Georgia (372)
Hawaii (3)
Idaho (46)
Illinois (695)
India (48)
Indiana (314)
Iowa (14)
Japan (397)
Kansas (100)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1188)
Massachusetts (7806)
Michigan (306)
Minnesota (558)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2602)
New Mexico (12)
New York (2799)
North Carolina (1263)
North Dakota (4)
Northern California (5938)
Ohio (275)
Oklahoma (14)
Oregon (18)
Pennsylvania (2241)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4924)
Tennessee (119)
Texas (1915)
United States (38556)
Utah (357)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (919)
West Virginia (1)
Wisconsin (73)
484,434 Results for "xilis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Xilis Announces Formation of its Scientific Advisory Board
Xilis today announced the addition of four members to its newly formed Scientific Advisory Board (SAB).
December 15, 2022
·
5 min read
Business
Xilis and MD Anderson Announce Strategic Collaboration to Advance Novel Technology and Accelerate Therapeutic Development
Xilis and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to deploy Xilis’s proprietary MicroOrganoSphere™ (MOS) technology in support of preclinical research to accelerate the development of novel cancer therapies.
February 15, 2023
·
5 min read
Business
Xilis Announces Breast Cancer Oncologist Dr. Daniel F. Hayes to Join Clinical Advisory Board
Xilis expands CAB to five members to help company develop its MicroOrganoSphere™ technology.
June 8, 2022
·
4 min read
Bio NC
Xilis Participates in €325MM Oncode-PACT Consortium to Accelerate the Development of Cancer Drugs
Xilis, Inc. announced that it is participating in the recently announced public-private Oncode-PACT.
May 3, 2022
·
4 min read
Bio NC
Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million
Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere™ (MOS™) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million.
July 13, 2022
·
4 min read
Bio NC
Xilis Presents Data at ESMO 2021 Demonstrating Capabilities of MicroOrganoSphere™ Technology for Cancer Drug Screening
Xilis, Inc. announced today the presentation of data on the company’s proprietary MOS technology. Data were presented at the 2021 European Society for Medical Oncology (ESMO) Congress in an oral presentation and two poster presentations.
September 20, 2021
·
4 min read
Bio NC
Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere™ Technology
Xilis, Inc. today announced the close of a $70 million Series A financing.
July 8, 2021
·
5 min read
Press Releases
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
June 29, 2026
·
5 min read
Press Releases
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
August 12, 2026
·
12 min read
Press Releases
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 6, 2026
July 7, 2026
·
1 min read
1 of 48,444
Next
